RECRUITING

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.

Official Title

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

Quick Facts

Study Start:2021-08-18
Study Completion:2025-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04810858

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 59 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * verified HIV status
  2. * Current marijuana use (MJ+ groups only)
  3. * No current marijuana use (MJ- groups only)
  4. * current engagement in HIV care (HIV+ participants only)
  5. * receipt of cART as first-line of treatment (HIV+ participants only)
  6. * stable cART regimen (HIV+ participants only)
  7. * undetectable HIV RNA viral load for \>1 year (HIV+ participants only)
  1. * Lifetime abuse for any illicit drug other than marijuana
  2. * \<9th grade education; illiteracy or lack of fluency in English
  3. * history of moderate or severe head trauma
  4. * unstable or serious neurological disorders
  5. * severe mental illness
  6. * systemic autoimmune diseases
  7. * immunotherapy
  8. * MRI contraindications

Contacts and Locations

Study Contact

Christina S Meade, PhD
CONTACT
336-716-0695
cmeade@wakehealth.edu
Sheri L Towe, PhD
CONTACT
336-716-4331
stowe@wakehealth.edu

Principal Investigator

Christina S Meade, PhD
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Biotech Place
Winston-Salem, North Carolina, 27101
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Christina S Meade, PhD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-08-18
Study Completion Date2025-05-31

Study Record Updates

Study Start Date2021-08-18
Study Completion Date2025-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Cannabis
  • HIV
  • Inflammation
  • Cognition
  • Neuroimaging